Compare iShares MSCI Indonesia ETF (EIDO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Merck & Co., Inc. — how do they compare? iShares MSCI Indonesia ETF trades at $11.84 (market cap $409.22M), while Merck & Co., Inc. trades at $144.98 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 858.4× iShares MSCI Indonesia ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 75 Days and Merck & Co., Inc. for 98 Days on average.
| EIDO | MRK | |
|---|---|---|
Market Cap | $409.22M | $351.28B |
Volume | 879,527 | 7,969,665 |
52-Week High | $19.22 | $156.43 |
52-Week Low | $10.80 | $82.49 |
Typical Hold Time | 75 Days | 98 Days |
Sector | — | Health |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.82, down 0.34% with bearish technical signals from moving averages. The ETF faces weak price action despite attractive valuation metrics, with technical indicators showing mixed signals including a neutral RSI but bearish ADX readings. Trading volume declined 21% below average, indicating reduced investor interest.
The outlook remains cautious given persistent technical downtrend and Indonesia's limited benefit from commodity gains. While valuation appears attractive at 8.7x P/E, the 44% financials weighting and modest 5.9% long-term EPS growth constrain upside potential. Key risks include sector concentration and regional capital outflows from Asian equities.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
